Itamar Medical Stock

Itamar Medical Net Margin

Delisted

The Net Profit Margin of Itamar Medical (ITMR.TA) as of Aug 25, 2026 is -26.66 %. In the previous year, Net Profit Margin was -16.85 % — a change of 58.18% (lower).

Net Margin

-26.66 %

YoY

58.18%

Last updated:

Net Profit Margin of Itamar Medical is 2026 -26.66 % . Net Profit Margin of Itamar Medical was 2025 -16.85 % . It decreases by 58.18% lower compared to the previous year.

Itamar Medical's net margin stands at -26.7%, up from -78.1% several years earlier.

The Itamar Medical Net Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Margin
Date
Net Margin
Jan 1, 2013
-0.97 USD
Jan 1, 2014
-19.99 USD
Jan 1, 2015
-13.37 USD
Jan 1, 2016
-78.11 USD
Jan 1, 2017
-25.61 USD
Jan 1, 2018
-7.15 USD
Jan 1, 2019
-16.85 USD
Jan 1, 2020
-26.66 USD
The Itamar Medical Net Margin history
YEARNet MarginYoY
-26.66 %+58.18%
-16.85 %+135.78%
-7.15 %-72.09%
-25.61 %-67.22%
-78.11 %+484.22%
-13.37 %-33.10%
-19.99 %+1,963.50%
-0.97 %-2,601.38%
0.04 %-125.64%
-0.15 %-187.35%
0.17 %-114.40%
-1.20 %+24.28%
-0.97 %+38.62%
-0.70 %+312.59%
-0.17 %-90.31%
-1.74 %-19.53%
-2.17 %-79.73%
-10.69 %
Access this data via the Eulerpool API

Itamar Medical Stock analysis

What does Itamar Medical do? Itamar Medical Ltd is a company specialized in the development and marketing of non-invasive diagnostic and monitoring solutions for sleep disorders, heart diseases, and peripheral vascular diseases. The company was founded in Israel in 1997. The history of Itamar Medical begins with the development of the PAT system (Peripheral Arterial Tone), a device that uses the peripheral arterial tonometer to measure blood flow. With this system, doctors were able to record patients' sleep for the first time and diagnose sleep disorders such as obstructive sleep apnea syndrome (OSAS) or restless leg syndrome (RLS). Over the years, the company has expanded its offerings and developed various solutions to improve the diagnosis and monitoring of heart and vascular diseases. Itamar Medical's products now include the EndoPAT, WatchPAT, and Total Sleep Solution, among others. The EndoPAT is a non-invasive medical device that measures the endothelial function state of patients. This refers to the ability of blood vessels to dilate when needed to increase blood flow. The EndoPAT allows doctors to assess the cardiovascular health status of patients and predict the risk of cardiovascular diseases. The WatchPAT is a wearable sleep monitor that wirelessly connects to an app. The device records the sleep architecture of patients and automatically detects sleep apnea episodes, which are then displayed on the app. The WatchPAT enables doctors to improve the sleep quality of patients and diagnose sleep disorders. Itamar Medical's Total Sleep Solution offers a comprehensive solution for the management of sleep disorders. The solution includes the WatchPAT tracker, the PAT procedures for sleep disorder diagnosis, and the EndoPAT procedures for assessing cardiovascular health. This combination of technologies allows doctors to treat their patients holistically and improve their cardiovascular health and sleep quality. Itamar Medical has also formed partnerships with other companies to enhance its solutions and promote new developments. Currently, the company is collaborating with Teva Pharmaceutical Industries to develop a new formulation of Sildenafil, a medication used for treating erectile dysfunction. Overall, Itamar Medical has experienced strong growth in recent years. The company has branches in the USA, Europe, and Asia and is constantly working to expand its offerings and improve its technology for the diagnosis and monitoring of heart and sleep disorders. In summary, Itamar Medical is an innovative provider of non-invasive diagnostic and monitoring solutions for sleep disorders, heart diseases, and peripheral vascular diseases. With its wide range of products and partnerships with other companies, the company is well-positioned to continue growing and expanding in the coming years. Itamar Medical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Itamar Medical stock

Net Profit Margin of Itamar Medical is -26.66 % in 2026.

Net Profit Margin of Itamar Medical changed from -16.85 % to -26.66 %, representing a 58.18% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Net Profit Margin Itamar Medical since 2006 – with annual values, charts, and detailed analysis.

Net Margin measures the percentage of revenue that becomes net profit after all expenses. It is the ultimate measure of a company's profitability.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Profit Margin's Itamar Medical with sector peers and the industry average to assess whether it is attractive.

To evaluate Net Profit Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Net Profit Margin.

Access this data via the Eulerpool API

Margins — Itamar Medical

All Key Metrics — Itamar Medical